Gene Salkind - Jan 27, 2023 Form 4 Insider Report for Coeptis Therapeutics Holdings, Inc. (COEP)

Role
Director
Signature
/s/ Gene Salkind
Stock symbol
COEP
Transactions as of
Jan 27, 2023
Transactions value $
$0
Form type
4
Date filed
1/31/2023, 10:03 AM
Previous filing
Nov 7, 2022
Next filing
Apr 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COEP Non-qualified Stock Options (right to buy) Award +30K 30K Jan 27, 2023 Common Stock 30K $1.60 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 27, 2023, the reporting person received a grant of 30,000 stock options, as non-qualified options, under the 2022 equity incentive plan.
F2 The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.
F3 Non-qualified options will vest over 1 year, in four equal installments, with the first 25% vesting on 3/31/2023, the next 25% vesting on 6/30/2023, the next 25% vesting on 9/30/23, and the final 25% vesting on 12/31/23.
F4 Expiration date is ten years from the day of grant.